AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38642555 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-computer interface (BCI) rehabilitation training
Number of subjects: 296
Study 38642555 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation training (Control)
Number of subjects: 296
Study 38642555 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI group
Number of subjects: 296
Study 38642555 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 296
Study 38642841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 442
Study 38642841 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 442
Study 38642860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittently scanned continuous glucose monitoring (is-CGM) for 6 weeks followed by one is-CGM/month till 24 weeks.
Number of subjects: 176
Study 38642860 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG) with 4 SMBG/day.
Number of subjects: 176
Study 38642889 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation Facilitation (IF)
Number of subjects: 3108
Study 38642889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustainability Phase
Number of subjects: 3108
Study 38642889 — intervention group
Group type: COMPARATOR
Intervention: Pre-Implementation Phase
Number of subjects: 3108
Study 38642937 — intervention group
Group type: EXPERIMENTAL
Intervention: ivonescimab 20 mg/kg every 2 weeks
Number of subjects: 51
Study 38642937 — intervention group
Group type: EXPERIMENTAL
Intervention: ivonescimab
Number of subjects: 51
Study 38642994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length screening program
Number of subjects: 1334
Study 38642994 — intervention group
Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 1334
Study 38642998 — intervention group
Group type: EXPERIMENTAL
Intervention: DYSPHAGING educational sheet intervention for screening and prevention of sarcopenic dysphagia
Number of subjects: 102
Study 38643014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep/circadian regulation assessment through questionnaires, ECG recording, and actigraphy watch worn for 7 days before surgery.
Number of subjects: 0
Study 38643014 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples collected preoperatively and postoperatively to gather information about Alzheimer's disease (AD) variant genes.
Number of subjects: 0
Study 38643086 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Stretch (HIS) device
Number of subjects: 34
Study 38643086 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy (PT) alone
Number of subjects: 34
Study 38643086 — intervention group
Group type: EXPERIMENTAL
Intervention: HIS device + PT
Number of subjects: 34
Study 38643086 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (HIS, PT, HIS + PT)
Number of subjects: 34
Study 38643116 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus paracasei GMNL-143 toothpaste
Number of subjects: 0
Study 38643116 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 0
Study 38643184 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management approach including exercise, education, and activity modification
Number of subjects: 130
Study 38643184 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study 38643242 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided ICBT
Number of subjects: 74
Study 38643242 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided ICBT
Number of subjects: 74
Study 38643311 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib 400 mg BID (4 days on/3 days off)
Number of subjects: 21
Study 38643311 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 1 mg (alone on day 1, and on days 8 and 12 with capivasertib)
Number of subjects: 21
Study 38643346 — intervention group
Group type: COMPARATOR
Intervention: Ruxolitinib (RUX) 15 mg twice daily and methylprednisolone (MP) 40 mg every other day
Number of subjects: 29
Study 38643346 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of Lenalidomide (LEN) 10 mg once daily on days 1-21 within a 28-day cycle to RUX and MP
Number of subjects: 29
Study 38643510 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavorixafor
Number of subjects: 31
Study 38643510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 38643547 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1222 COVID-19 vaccine (two doses)
Number of subjects: 0
Study 38643547 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 38643782 — intervention group
Group type: EXPERIMENTAL
Intervention: LFTD diet (low FODMAP diet plus traditional dietary advice)
Number of subjects: 294
Study 38643782 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 294
Study 38643782 — intervention group
Group type: COMPARATOR
Intervention: Optimised medical treatment
Number of subjects: 294
Study 38644146 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg orally twice daily with ADT + docetaxel
Number of subjects: 1305
Study 38644146 — intervention group
Group type: COMPARATOR
Intervention: Placebo with ADT + docetaxel
Number of subjects: 1305
Study 38644588 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line infliximab treatment
Number of subjects: 89
Study 38644588 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 89
Study 38644625 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Number of subjects: 0
Study 38644625 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Number of subjects: 0
Study 38644625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38644670 — intervention group
Group type: EXPERIMENTAL
Intervention: Endomethasone N RCS (EndoN)
Number of subjects: 286
Study 38644670 — intervention group
Group type: COMPARATOR
Intervention: Endomethasone SP RCS (EndoSP)
Number of subjects: 286
Study 38644692 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 238
Study 38644981 — intervention group
Group type: EXPERIMENTAL
Intervention: QUTE-CE MRA
Number of subjects: 15
Study 38644981 — intervention group
Group type: COMPARATOR
Intervention: Ferumoxytol T1-weighted
Number of subjects: 15
Study 38644981 — intervention group
Group type: COMPARATOR
Intervention: Time-of-flight
Number of subjects: 15
Study 38645135 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored Family Health History toolkit
Number of subjects: 195
Study 38645135 — intervention group
Group type: COMPARATOR
Intervention: Current standard Family Health History toolkit
Number of subjects: 195
Study 38645256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar deep brain stimulation (DBS) in the dorsal dentate nucleus
Number of subjects: 10
Study 38645256 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study 38645550 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive sensory environment (ASE)
Number of subjects: 60
Study 38645550 — intervention group
Group type: COMPARATOR
Intervention: Control (no ASE)
Number of subjects: 60
Study 38646922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation Index-guided HPSD ablation
Number of subjects: 238
Study 38647051 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 0
Study 38647051 — intervention group
Group type: COMPARATOR
Intervention: Investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir)
Number of subjects: 0
Study 38647289 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-burr hole sonography
Number of subjects: 20
Study 38647467 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher ratings of classroom behaviors
Number of subjects: 60
Study 38647467 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific features of behavioral inhibition
Number of subjects: 60
Study 38647487 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week community-based resilience group intervention
Number of subjects: 80
Study 38647487 — intervention group
Group type: COMPARATOR
Intervention: waitlist-control group
Number of subjects: 80
Study 38647654 — intervention group
Group type: EXPERIMENTAL
Intervention: AG-920 (Articaine) ophthalmic solution
Number of subjects: 0
Study 38647654 — intervention group
Group type: COMPARATOR
Intervention: Active control (not specified)
Number of subjects: 0
Study 38647975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab treatment for 60 weeks
Number of subjects: 0
Study 38648030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tirofiban
Number of subjects: 425
Study 38648030 — intervention group
Group type: COMPARATOR
Intervention: Oral aspirin
Number of subjects: 425
Study 38648061 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker group (Stockholm3 test with systematic biopsy)
Number of subjects: 12743
Study 38648061 — intervention group
Group type: COMPARATOR
Intervention: MRI-enhanced group (PSA test followed by MRI with systematic and targeted biopsy)
Number of subjects: 12743
Study 38648081 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding for 4 weeks (n=15)
Number of subjects: 30
Study 38648081 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 30
Study 38648103 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app (EVITE)
Number of subjects: 128
Study 38648264 — intervention group
Group type: EXPERIMENTAL
Intervention: PreMiCC (prediction score for a mild course of Crohn's disease)
Number of subjects: 201
Study 38648264 — intervention group
Group type: EXPERIMENTAL
Intervention: PreMiCC score ≤2
Number of subjects: 201
Study 38648264 — intervention group
Group type: EXPERIMENTAL
Intervention: PreMiCC score >2
Number of subjects: 201
Study 38648264 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier curve for therapy escalation
Number of subjects: 201
Study 38648575 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan (70 mg/m2 IV)
Number of subjects: 461
Study 38648575 — intervention group
Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 461
Study 38648575 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan
Number of subjects: 461
Study 38648575 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan and Topotecan
Number of subjects: 461
Study 38648580 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment continued
Number of subjects: 166
Study 38648580 — intervention group
Group type: COMPARATOR
Intervention: Natalizumab treatment stopped
Number of subjects: 166
Study 38648814 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (1 g over 10 min followed by 1 g over 8 h)
Number of subjects: 201
Study 38648814 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline; matched dosing regimen)
Number of subjects: 201
Study 38648814 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid
Number of subjects: 201
Study 38648814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 38648863 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg linzagolix with add-back therapy (ABT)
Number of subjects: 486
Study 38648863 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg linzagolix alone
Number of subjects: 486
Study 38648863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study 38648998 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home-based inspiratory muscle training program
Number of subjects: 26
Study 38648998 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 26
Study 38649069 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (10 IU/mL and higher)
Number of subjects: 0
Study 38649069 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinase I treatment
Number of subjects: 0
Study 38649069 — intervention group
Group type: COMPARATOR
Intervention: Hologic Panther Aptima SARS-CoV-2 assay
Number of subjects: 0
Study 38649069 — intervention group
Group type: COMPARATOR
Intervention: Roche Cobas LIAT
Number of subjects: 0
Study 38649085 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 0
Study 38649085 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy
Number of subjects: 0
Study 38649096 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary docosahexaenoic acid (DHA); specific dosage and duration not mentioned.
Number of subjects: 0
Study 38649279 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-derived positron-emission tomography (PET) parameters assessed 6-8 weeks after the start of immune checkpoint inhibitors (ICPIs)
Number of subjects: 110
Study 38649279 — intervention group
Group type: COMPARATOR
Intervention: Conventional PERCIST criteria
Number of subjects: 110
Study 38649340 — intervention group
Group type: EXPERIMENTAL
Intervention: D-KRd (daratumumab+carfilzomib/lenalidomide/dexamethasone)
Number of subjects: 243
Study 38649340 — intervention group
Group type: EXPERIMENTAL
Intervention: D-RVd (daratumumab+lenalidomide/bortezomib/dexamethasone)
Number of subjects: 243
Study 38649506 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair with iliac branch devices (IBD)
Number of subjects: 297
Study 38649522 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter ocrelizumab infusion (2-h)
Number of subjects: 745
Study 38649522 — intervention group
Group type: COMPARATOR
Intervention: Conventional ocrelizumab infusion (3.5-h)
Number of subjects: 745
Study 38649561 — intervention group
Group type: EXPERIMENTAL
Intervention: Layered plaques (n=241)
Number of subjects: 195
Study 38649561 — intervention group
Group type: COMPARATOR
Intervention: Non-layered plaques (n=234)
Number of subjects: 195
Study 38649595 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilematovir (low or high dose)
Number of subjects: 246
Study 38649595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 38649657 — intervention group
Group type: EXPERIMENTAL
Intervention: Vosoritide (daily per-kg doses)
Number of subjects: 0
Study 38649657 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-band dosing regimen
Number of subjects: 0
Study 38649734 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine
Number of subjects: 0
Study 38649734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38649756 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of factors influencing quality of life in individuals with long-term SCI
Number of subjects: 16
Study 38649826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate cervical plexus block (IC) with 15 ml of bupivacaine 0.25% administered to each side
Number of subjects: 58
Study 38649826 — intervention group
Group type: COMPARATOR
Intervention: Cervical erector spinae block (ES) with 15 ml of bupivacaine 0.25% administered to each side at the C6 level
Number of subjects: 58
Study 38649826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate cervical plexus block (IC)
Number of subjects: 58
Study 38649826 — intervention group
Group type: COMPARATOR
Intervention: Cervical erector spinae block (ES)
Number of subjects: 58
Study 38649937 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-guided targeted laser (IGTL) combined with intravitreal injections (IVI) of anti-VEGF
Number of subjects: 270
Study 38649937 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal injections (IVI) of anti-VEGF solely
Number of subjects: 270
Study 38649937 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IGTL + IVI and IVI only)
Number of subjects: 270
Study 38649940 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 958
Study 38649940 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNO
Number of subjects: 958
Study 38649940 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV+HFNO
Number of subjects: 958
Study 38649940 — intervention group
Group type: COMPARATOR
Intervention: COT
Number of subjects: 958
Study 38650031 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 + neratinib
Number of subjects: 49
Study 38650037 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus lenvatinib (tislelizumab 200 mg every three weeks plus lenvatinib 12 mg for bodyweight ≥ 60 kg or 8 mg for bodyweight < 60 kg once daily)
Number of subjects: 64
Study 38650037 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus lenvatinib
Number of subjects: 64
Study 38650039 — intervention group
Group type: EXPERIMENTAL
Intervention: Early progressive resistance exercises (weekly supervised physiotherapy sessions and home exercises)
Number of subjects: 16
Study 38650039 — intervention group
Group type: EXPERIMENTAL
Intervention: Early progressive resistance exercises
Number of subjects: 16
Study 38650042 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise training program (6 weeks)
Number of subjects: 24
Study 38650042 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 24
Study 38650049 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 0
Study 38650055 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day edoxaban for 12 months
Number of subjects: 601
Study 38650055 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day edoxaban for 12 months
Number of subjects: 601
Study 38650075 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) treatment for 6 months postoperatively
Number of subjects: 213
Study 38650075 — intervention group
Group type: COMPARATOR
Intervention: Control (no PEMF treatment)
Number of subjects: 213
Study 38650518 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPSE/sPAP <0.55
Number of subjects: 481
Study 38650579 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Number of subjects: 150
Study 38650579 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 150
Study 38650640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mangrove sword bean snack bar
Number of subjects: 31
Study 38650640 — intervention group
Group type: COMPARATOR
Intervention: Sword bean food bar (Control)
Number of subjects: 31
Study 38650640 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 31
Study 38650969 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (OX)
Number of subjects: 1200
Study 38650969 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers (BB)
Number of subjects: 1200
Study 38650969 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers and Oxandrolone (BBOX)
Number of subjects: 1200
Study 38651107 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT-A) injection, specifically abobotulinumtoxinA, median total dose 500 units, injected into biceps brachii (83.3%), flexor carpi radialis (72.9%), and flexor digitorum profundus (66.7%).
Number of subjects: 51
Study 38651515 — intervention group
Group type: COMPARATOR
Intervention: SPG4 patients
Number of subjects: 84
Study 38651515 — intervention group
Group type: COMPARATOR
Intervention: SPG5 patients
Number of subjects: 84
Study 38651515 — intervention group
Group type: EXPERIMENTAL
Intervention: Controls
Number of subjects: 84
Study 38651909 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38651976 — intervention group
Group type: EXPERIMENTAL
Intervention: ide-cel
Number of subjects: 0
Study 38651976 — intervention group
Group type: COMPARATOR
Intervention: standard of care regimens
Number of subjects: 0
Study 38652090 — intervention group
Group type: EXPERIMENTAL
Intervention: LAWT-guided vHPSD PVI
Number of subjects: 162
Study 38652090 — intervention group
Group type: COMPARATOR
Intervention: CLOSE protocol
Number of subjects: 162
Study 38652133 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CRT) followed by radical resection
Number of subjects: 604
Study 38652133 — intervention group
Group type: EXPERIMENTAL
Intervention: AI models (LR, LGB, MLP, XGB)
Number of subjects: 604
Study 38652133 — intervention group
Group type: EXPERIMENTAL
Intervention: AI models (DTC, RF, SVM)
Number of subjects: 604
Study 38652133 — intervention group
Group type: EXPERIMENTAL
Intervention: AI models overall
Number of subjects: 604
Study 38652200 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radio-guided surgery (RGS) using a β-probe
Number of subjects: 20
Study 38652235 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress functional magnetic resonance imaging (fMRI) paradigm using the Montreal Imaging Stress Task (MIST)
Number of subjects: 25
Study 38652232 — intervention group
Group type: EXPERIMENTAL
Intervention: ELCOVID score (risk-scoring system)
Number of subjects: 1014
Study 38652232 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1014
Study 38652232 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium
Number of subjects: 1014
Study 38652232 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets
Number of subjects: 1014
Study 38652232 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer level
Number of subjects: 1014
Study 38652232 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs of right ventricular strain (RVS)
Number of subjects: 1014
Study 38652232 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG signs of previous myocardial necrosis
Number of subjects: 1014
Study 38652308 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvinylidene fluoride (PVDF) mesh loaded with iron particles in an onlay position
Number of subjects: 185
Study 38652493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent unilateral subthalamic nucleus deep brain stimulation
Number of subjects: 14
Study 38652493 — intervention group
Group type: COMPARATOR
Intervention: Nights without stimulation
Number of subjects: 14
Study 38652499 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium oxybate (LXB)
Number of subjects: 62
Study 38652499 — intervention group
Group type: COMPARATOR
Intervention: High-sodium oxybate (SXB)
Number of subjects: 62
Study 38652519 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic biosynthetic mesh placement during stoma reversal
Number of subjects: 174
Study 38652519 — intervention group
Group type: COMPARATOR
Intervention: Primary stoma closure without mesh
Number of subjects: 174